Overview
No overview information available.
Indication
用于治疗系统性红斑狼疮（SLE）、类风湿性关节炎等多种自身免疫疾病。 小知识：SLE症状表现多样，如面部出现红斑、关节肿痛、对光过敏、口腔溃疡等，随着病情的进展可导致肾脏、心血管等全身多系统、多器官的不可逆损害，严重威胁生命。目前，我国SLE患病人数超过100万，居全球之首，且多发于15-45岁的年轻女性，女性患病率为男性的10.1倍。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/08/08 | Not Applicable | Active, not recruiting | |||
2025/08/01 | Not Applicable | Active, not recruiting | |||
2025/07/22 | Not Applicable | ENROLLING_BY_INVITATION | |||
2025/07/08 | Not Applicable | Not yet recruiting | Guixia Ding | ||
2025/06/06 | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | ||
2024/12/09 | Phase 4 | Not yet recruiting | |||
2024/11/07 | Phase 4 | Active, not recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University | ||
2024/10/24 | Phase 1 | Active, not recruiting | |||
2024/10/23 | Not Applicable | Recruiting | |||
2024/09/26 | Phase 2 | Not yet recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.